Log In
BCIQ
Print this Print this
 

oxaliplatin (MBP-426)

  Manage Alerts
Collapse Summary General Information
Company Mebiopharm Co. Ltd.
DescriptionTransferrin-conjugated nano particle formulation of oxaliplatin
Molecular Target
Mechanism of Action 
Therapeutic ModalityNanotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationGastric cancer
Indication DetailsTreat gastric cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today